Drug: tisotumab_vedotin

=== Drug Interactions ===
7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Closely monitor for TIVDAK adverse reactions. ( 7.1 ) 7.1 Effects of Other Drugs on TIVDAK Strong CYP3A4 Inhibitors MMAE is a CYP3A4 substrate. Concomitant use of TIVDAK with strong CYP3A4 inhibitors may increase unconjugated MMAE exposure [see Clinical Pharmacology (12.3) ] , which may increase the risk of TIVDAK adverse reactions. Closely monitor patients for adverse reactions of TIVDAK when used concomitantly with strong CYP3A4 inhibitors.
